Harriet Gee - Publications

2008-2010 University of Oxford, Oxford, United Kingdom 

13 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Dhawan A, Scott J, Sundaresan P, Veness M, Porceddu S, Hau E, Harris AL, Buffa FM, Gee HE. Role of gene signatures combined with pathology in classification of oropharynx head and neck cancer. Scientific Reports. 10: 10226. PMID 32576885 DOI: 10.1038/S41598-020-66983-X  0.361
2020 Shen H, Chang C, Gee H, McKelvey K, O’Neill G, Prior V, Blackburn A, Hau E. DIPG-13. TARGETING HYPOXIA AND MITOCHONDRIA WITH REPURPOSED METABOLIC DRUGS AS AN APPROACH TO RADIOSENSITIZATION FOR DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPG) Neuro-Oncology. 22: iii289-iii289. DOI: 10.1093/neuonc/noaa222.063  0.327
2018 Dhawan A, Scott JG, Sundaresan P, Veness M, Porceddu S, Hau E, Ahern V, Harris AL, Buffa FM, Gee HE. Are signatures of radiosensitivity ready for routine clinical use? A pragmatic comparison of clinical, pathological, and gene signature predictors of outcome in oropharynx head and neck cancers. Journal of Clinical Oncology. 36: e18046-e18046. DOI: 10.1016/J.Ijrobp.2018.06.338  0.337
2018 Dhawan A, Scott J, Sundaresan P, Veness M, Porceddu S, Hau E, Ahern V, Harris A, Buffa F, Gee H. Are Signatures of Radiosensitivity Ready for Routine Clinical Use? a Pragmatic Comparison of Clinical, Pathological and Gene Signature Predictors of Outcome in Oropharynx Head and Neck Cancers International Journal of Radiation Oncology*Biology*Physics. 102: S137-S138. DOI: 10.1016/j.ijrobp.2018.06.338  0.337
2017 Pajic M, Froio D, Daly S, Doculara L, Millar E, Graham PH, Drury A, Steinmann A, de Bock CE, Boulghourjian A, Zaratzian A, Carroll S, Toohey J, O'Toole SA, Harris AL, ... ... Gee HE, et al. miR-139-5p modulates radiotherapy resistance in breast cancer by repressing multiple gene networks of DNA repair and ROS defense. Cancer Research. PMID 29180477 DOI: 10.1158/0008-5472.CAN-16-3105  0.585
2015 Zhang X, Gee H, Rose B, Lee CS, Clark J, Elliott M, Gamble JR, Cairns MJ, Harris A, Khoury S, Tran N. Regulation of the tumour suppressor PDCD4 by miR-499 and miR-21 in oropharyngeal cancers. Bmc Cancer. 16: 86. PMID 26867589 DOI: 10.1186/s12885-016-2109-4  0.552
2015 Gee HE, Buffa FM, Harris AL, Toohey JM, Carroll SL, Cooper CL, Beith J, McNeil C, Carmalt H, Mak C, Warrier S, Holliday A, Selinger C, Beckers R, Kennedy C, et al. MicroRNA-Related DNA Repair/Cell-Cycle Genes Independently Associated With Relapse After Radiation Therapy for Early Breast Cancer. International Journal of Radiation Oncology, Biology, Physics. 93: 1104-14. PMID 26581147 DOI: 10.1016/j.ijrobp.2015.08.046  0.412
2013 Kumar K, Wigfield S, Gee HE, Devlin CM, Singleton D, Li JL, Buffa F, Huffman M, Sinn AL, Silver J, Turley H, Leek R, Harris AL, Ivan M. Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts. Journal of Molecular Medicine (Berlin, Germany). 91: 749-58. PMID 23361368 DOI: 10.1007/s00109-013-0996-2  0.562
2011 Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, Sheldon H, Taylor M, Harris AL, Ragoussis J. microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Research. 71: 5635-45. PMID 21737487 DOI: 10.1158/0008-5472.CAN-11-0489  0.735
2011 Gee HE, Buffa FM, Camps C, Ramachandran A, Leek R, Taylor M, Patil M, Sheldon H, Betts G, Homer J, West C, Ragoussis J, Harris AL. The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. British Journal of Cancer. 104: 1168-77. PMID 21407217 DOI: 10.1038/sj.bjc.6606076  0.498
2010 Favaro E, Ramachandran A, McCormick R, Gee H, Blancher C, Crosby M, Devlin C, Blick C, Buffa F, Li JL, Vojnovic B, Pires das Neves R, Glazer P, Iborra F, Ivan M, et al. MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU. Plos One. 5: e10345. PMID 20436681 DOI: 10.1371/Journal.Pone.0010345  0.553
2010 Gee HE, Camps C, Buffa FM, Patiar S, Winter SC, Betts G, Homer J, Corbridge R, Cox G, West CM, Ragoussis J, Harris AL. hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer. 116: 2148-58. PMID 20187102 DOI: 10.1002/cncr.25009  0.739
2008 Gee HE, Camps C, Buffa FM, Colella S, Sheldon H, Gleadle JM, Ragoussis J, Harris AL. MicroRNA-10b and breast cancer metastasis. Nature. 455: E8-9; author reply E. PMID 18948893 DOI: 10.1038/nature07362  0.396
Show low-probability matches.